CapsoVision, Inc. (CV) on Thursday reported its financial results for the third quarter ended September 30, 2025.
The company reported a net loss of $7.9 million or $0.17 per share, compared with a net loss of $5.8 million or $2.79 per share in the same quarter last year.
Net revenue increased to $3.54 million, up from $2.97 million in the prior-year period. Gross profit rose to $1.91 million, compared with $1.66 million last year, while operating expenses increased to $9.93 million from $7.46 million.
CapsoVision highlighted continued investment in research and development, with total R&D spending rising to $6.1 million from $4.5 million in the same quarter last year.
The company said it remains focused on advancing its capsule endoscopy technology and expanding market adoption.
CV closed Thursday at $5.67, up 2.35%, and traded after hours at $4.91, down 13.4% on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.